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Purpose: To evaluate the therapeutic effect of intravitreal triamcinolone (IVT) injection 
for recent branch retinal vein occlusion (BRVO). 
Methods: In a randomized controlled clinical trial, 30 phakic eyes with recent (less 
than 10 weeks’ duration) BRVO were assigned to two groups. The treatment group 
(16 eyes) received 4 mg IVT and the control group (14 eyes) received subconjunctival 
sham injections. Changes in visual acuity (VA) were the main outcome measure. 
Results: VA and central macular thickness (CMT) changes were not significantly 
different between the study groups at any time point. Within group analysis showed 
significant VA improvement from baseline in the IVT group up to three months (P < 0.05); 
the amount of this change was -0.53 ± 0.46, -0.37 ± 0.50, -0.46 ± 0.50, and -0.29 ± 0.45 
logMAR at 1, 2, 3, and 4 months, respectively. Corresponding VA improvements in 
the control group were -0.20 ± 0.37, -0.11 ± 0.46, -0.25 ± 0.58, and -0.05 ± 0.50 logMAR 
(all P values > 0.05). Significant reduction in CMT was noticed only in the treatment 
group (-172 ± 202 µm, P = 0.029) and at 4 months. Ocular hypertension occurred in 
4 (25%) and 2 (14.3%) eyes in the IVT and control groups, respectively.
Conclusion: A single IVT injection had a non-significant beneficial effect on VA 
and CMT in acute BRVO as compared to the natural history of the condition. The 
3-month deferred treatment protocol advocated by the Branch Vein Occlusion Study 
Group may be a safer option than IVT injection considering its potential side effects.
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INTRODuCTION
Branch retinal vein occlusion (BRVO) has 
a prevalence of 0.6%1 to 1.6%2 and is the 
second most common type of retinal vascular 
abnormality following diabetic retinopathy.3 
Visual loss following a recent BRVO may result 
from macular edema, foveal hemorrhage, and 
macular ischemia. The Branch Vein Occlusion 
Study (BVOS) Group demonstrated that laser 
photocoagulation improves visual outcomes 
to a significant degree in eyes with BRVO, 
provided that foveal vascularity is intact and 
presenting visual acuity (VA) is 20/40 to 
20/200.3 Therefore, such management is limited 
to eyes with adequate macular perfusion and 
a specified range of vision. The same study 
suggested that therapy should be delayed IVT for Acute BRVO; Ramezani et al
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for at least three months to permit maximum 
spontaneous resolution of retinal edema and 
hemorrhage. On the other hand, reduction of 
edema early after vein occlusion until restoration 
of collaterals seems to be of great importance 
in preventing permanent macular damage in 
these eyes,4,5 therefore postponing therapy for 
three months may adversely affect the outcomes 
of any intervention.
Administration of intravitreal or retrobulbar 
corticosteroids for treatment of macular edema 
secondary to retinal vascular disorders has 
gained popularity in recent years.5-9 Many 
studies have shown improvement in VA and 
macular edema in eyes with BRVO following 
intravitreal triamcinolone (IVT) injections.10-21 
Most of them, however, have been retrospective 
case reports or small case series with no control 
group, making it difficult to distinguish whether 
the observed outcomes represent the natural 
history of the condition or a true response to 
therapy. The Standard Care vs. Corticosteroid 
for Retinal Vein Occlusion (SCORE) study22 
undertook a multicenter randomized clinical 
trial to compare the safety and efficacy of 1 mg 
and 4 mg preservative-free IVT with that of grid 
macular photocoagulation (MPC). The study 
demonstrated no difference in VA among the 
study groups at 12 months. It is noteworthy that 
this study did not exclude eyes with old BRVO. 
To the best of our knowledge, no prospective 
randomized clinical trial has been published 
to date comparing the effect of IVT with no 
treatment in recent-onset BRVO. We conducted 
this randomized controlled clinical trial to 
determine the outcomes of therapy with IVT 
and to compare them with the natural course 
of acute BRVO.
METhODS
This clinical trial was approved by the Review 
Board / Ethics Committee of the Ophthalmic 
Research Center. The study protocol and its 
goals and limitations were explained to all 
participants before enrollment and informed 
consent was obtained from each patient. 
All eyes suffering from BRVO of less than 10 
weeks’ duration were considered for enrollment. 
Exclusion criteria consisted of monocularity, 
previous intraocular surgery or laser therapy, 
VA ≥ 20/40, glaucoma or ocular hypertension, 
significant media opacity, pre-existing iris or 
retinal neovascularization, concomitant arterial 
occlusion, signs of chronicity such as presence 
of cilioretinal and/or retinal shunt vessels, 
coexisting retinal disorders, and non-compliance. 
The main outcome measure was best-
corrected logarithm of the minimum angle of 
resolution (logMAR) visual acuity. Secondary 
outcomes included central macular thickness 
(CMT), intraocular pressure (IOP), and 
the appearance of the iris and/or retinal 
neovascularization. Central macular thickness 
was determined by optical coherence 
tomography (OCT-2; Zeiss, Dublin, CA, USA).
A complete ophthalmic examination 
was performed in all subjects at baseline. 
Ancillary diagnostic tests included fluorescein 
angiography and optical coherence tomography 
(OCT). Judged by a retina specialist who was 
masked to the patients’ groups, BRVOs were 
classified as ischemic or non-ischemic based 
on the area of capillary non-perfusion at a 
cutoff value of 5 disc diameters on fluorescein 
angiography. The presence of cystoid macular 
edema was determined by a petaloid appearance 
on late phase angiograms.
Eligible eyes were randomly assigned 
to case and control groups. Under sterile 
conditions in the operating room, injections were 
performed after topical anesthesia and insertion 
of a lid speculum. In the case group, 0.1 cc 
(4 mg) triamcinolone acetonide was injected 
intravitreally through the superotemporal 
quadrant 4 mm posterior to the limbus using 
a 27-gauge needle. In the control eyes, a sham 
injection of 0.1 cc lidocaine 2% was given 
subconjunctivally. Ophthalmic examinations 
were repeated at 1, 2, 3, and 4 months. OCT 
mapping was repeated at 2 and 4 months. 
Retinal thickness was measured in the central 
1 mm circle of the 3.5 mm ring centered on the 
fixation point.
Statistical Analysis
We utilized mean (±SD) values to describe IVT for Acute BRVO; Ramezani et al
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quantitative data and percentages for qualitative 
data. Chi-square or Fisher’s Exact tests were 
used for qualitative data. The t-test was used 
for between-group comparisons and paired 
t-test was used for comparing quantitative 
data within the study groups, in univariate 
analysis. Adjustment for multiple within-group 
comparisons was performed by the Dunnett 
method. Data were analyzed using SPSS 15 
(SPSS Inc., Chicago, IL, USA). The statistical 
level of significance was preset at 0.05.
To be able to detect a 0.4 logMAR (about 
4 Snellen lines) difference in VA improvement 
between the study groups, a sample size of 14 
eyes in each group was required at a two sided 
5% level and study power of 85%.
RESuLTS
Thirty eyes, including 16 eyes in the IVT group 
and 14 in the control group, of 30 patients (18 
male and 12 female) with mean age of 59.6 ± 10.9 
(range, 40 to 78) years, fulfilled the study criteria 
and completed at least two examinations over 
a period of 4 months. Baseline characteristics 
of the study groups were comparable in the 
two groups and are summarized in table 1.
Mean best-corrected VA was compared 
before (month 0), and 1, 2, 3 and 4 months 
after intervention between the study groups 
(Fig 1). Initial VA was comparable between 
the two groups. Both groups showed an 
improvement in VA at one month which was 
more pronounced in the IVT group. Better VA 
in the treated group was maintained up to the 
last follow up, however intergroup differences 
failed to reach a significant level at any time 
interval. The greatest difference in mean best-
corrected VA between the groups occurred at 
month 1 (P = 0.087). 
Differences in VA changes from baseline at 
each monthly visit were compared within and 
between the study groups (Table 2). Within the 
study groups, only treated eyes demonstrated 
significant VA changes at every visit except 
at month 4. However, the differences in VA 
changes between the groups did not reach a 
significant level at any time interval.
Mean CMT values throughout the study 
are shown in figure 2. Differences in CMT 
changes before intervention, and 2 and 4 
months afterwards were compared within and 
between the two groups (Table 3). Throughout 
the study, mean CMT was reduced in both 
groups. At month 2, reduction in CMT was 
nearly equal in the two groups; however, CMT 
continued to diminish further in treated eyes 
up to month 4 and this change was statistically 
significant within this subgroup. Nevertheless, 
Figure 1.  Mean corrected visual acuity (logMAR) 
in controls and eyes treated with 4  mg intravitreal 
triamcinolone at five time intervals.
Treatment group
P‑value
Case Control
Eyes (N) 16 14
Mean age (years) 60.1 ± 9.8 59.2 ± 12.6 0.837*
Female/male 9/7 3/11 0.057†
Mean symptom duration 
(weeks)
5.4 ± 3.1 6.2 ± 2.9 0.501*
Mean IOP (mmHg) 13.6 ± 3.4 12.6 ± 2.2 0.399*
Positive APD 2 3 0.490†
Non-ischemic/ ischemic 9/7 4/10 0.159†
Mean VA (logMAR) 1.10 ± 0.52 1.09 ± 0.39 0.940*
Mean CMT (µ)  521 ± 113 563 ± 158 0.424*
Presence of CME‡ 6 of 12 4 of 10 0.691†
Table 1.  Comparison of baseline characteristics in the 
study groups
* ANOVA; † Fisher Exact test; ‡ undetermined in 8 eyes
N, number; IOP, intraocular pressure; APD, afferent pupillary 
defect; VA, visual acuity; CMT, central macular thickness; CME, 
cystoid macular edemaIVT for Acute BRVO; Ramezani et al
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differences in CMT changes between the two 
groups did not reach a significant level at any 
time interval.
The distribution of non-ischemic against 
ischemic BRVO was 9 vs. 7 in the treated group 
and 4 vs. 10 in the control group. Randomization 
seemed to have been unsuccessful in this 
regard but this was not statistically significant 
(P = 0.159, Fisher’s Exact test). A subgroup 
analysis was performed to detect the influence 
of this factor on VA and CMT changes (Table 4). 
Table 4 shows baseline values of VA and CMT 
and their changes up to month 4 in non-ischemic 
and ischemic eyes separately. Non-ischemic 
and ischemic eyes were significantly different 
in terms of mean VA and CMT at baseline. 
Although the degree of VA improvement and 
CMT reduction was greater in the ischemic 
subgroup, there was no significant difference 
between non-ischemic and ischemic eyes in 
terms of VA and CMT changes at month 4. 
This analysis demonstrated that the difference 
in VA and CMT changes between the groups 
at month 4 were significant only in the non-
ischemic but not in the ischemic subgroup. 
Serious injection-related complications 
such as vitreous hemorrhage, endophthalmitis, 
retinal detachment and significant cataract 
progression were not encountered. 
During the study period, an IOP higher than 
21 mmHg occurred in 4 (25%) and 2 (14.3%) 
eyes in IVT and control groups, respectively 
and none were accompanied by iris or angle 
neovascularization. The difference in mean IOP 
between the two groups reached a significant 
level (P = 0.035) only at the first month: 
17.6 ± 5.2 mmHg vs. 13.0 ± 4.7 mmHg in the 
Month
Case Control
P‑value between  
groups CMT changes (µ)
P‑value within  
group*
CMT changes (µ)
P‑value within  
group*
0 to 2 -134 ± 131 0.116 -139 ± 194 0.060 0.953
0 to 4 -172 ± 202 0.029 -93 ± 227 0.079 0.428
Table 3. Central macular thickness changes following intravitreal triamcinolone injection versus observation in acute 
branch retinal vein occlusion
* Based on Dunnett method
CMT, central macular thickness
Month
Case Control
P‑value between 
groups VA changes 
(logMAR)†
P‑value within 
group*
VA changes 
(logMAR)†
P‑value within 
group*
0 to 1 -0.53 ± 0.46 0.008 -0.20 ± 0.37 0.373 0.072
0 to 2 -0.37 ± 0.50 0.049 -0.11 ± 0.46 0.801 0.225
0 to 3 -0.46 ± 0.50 0.020 -0.25 ± 0.58 0.498 0.407
0 to 4 -0.29 ± 0.45 0.113 -0.05 ± 0.50 0.681 0.206
Table 2. Visual acuity changes following intravitreal triamcinolone injection versus observation in acute branch retinal 
vein occlusion
† A decrease in logMAR notation reflects an increase in VA; * Based on Dunnett method
VA, visual acuity
Figure 2. Mean central macular thickness in controls and 
eyes treated with 4 mg intravitreal triamcinolone at three 
time intervals.IVT for Acute BRVO; Ramezani et al
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IVT and control groups, respectively. 
Neovascularization of the iris occurred 
in three control eyes at 3 and 4 months; 
neovascularization of the retina appeared in 
one treated and one control eye at 4 months. 
All of these eyes underwent retinal laser 
photocoagulation after the study.
DISCuSSION
In this clinical trial, although IVT injection was 
associated with significant visual improvement 
up to 3 months and reduction in CMT 4 months 
after intervention, these changes failed to show 
superiority to those observed with the natural 
course of recent onset BRVO. We noticed a 
better response to IVT therapy in eyes with 
non-ischemic BRVO. 
Macular edema due to BRVO may resolve 
over a period of 6 to 24 months;23 however, 
vision may not improve because of irreversible 
retinal damage. The rationale behind the current 
trial was to initiate treatment before permanent 
macular damage occurs, therefore cases with 
more than 10 weeks’ duration were excluded. 
In a retrospective study, Oh et al4 
demonstrated that IVT is more effective in eyes 
with BRVO patients with less than 3 months’ 
duration of symptoms as compared to more 
chronic cases. They found VA improvement 
and CMT reduction at 1 month in both groups; 
however, this beneficial effect was maintained 
up to 6 months only in the early treatment group.
Scott et al22 conducted a multicenter, 
randomized clinical trial on 411 participants 
with BRVO (the SCORE study) and compared 
the safety and efficacy of 1 mg and 4 mg of 
preservative-free IVT with that of MPC. An 
increase in VA score ≥15 letters from baseline 
at 12 months was the main outcome measure, 
which was achieved in 29%, 26%, and 27% of 
the participants in the MPC, and 1 and 4 mg 
IVT groups, respectively. None of the pairwise 
comparisons between the three groups was 
significant. Considering the rates of adverse 
events in IVT, the authors concluded that MPC 
should remain the standard care for patients 
with macular edema secondary to BRVO. 
Not all of the cases in this study were naive 
BRVO, and not all were recent-onset disease. 
In our trial, however, we insisted on early 
intervention with IVT, before the development 
of irreversible macular changes, and compared 
it with no intervention which is the ongoing 
standard of care for recent BRVO based on 
BVOS recommendations.3
In a randomized clinical trial, Avitabile 
et al24 compared IVT to standard grid MPC 
for treatment of macular edema secondary to 
BRVO, diabetic retinopathy, and central retinal 
vein occlusion. Only 6 out of 63 eyes in this 
study were diagnosed with BRVO. For the 
entire study population, eyes receiving IVT 
had better VA and lower CMT values at all 
time points (P < 0.05). The major limitation of 
this study was that analysis was not conducted 
separately for different etiologies; therefore, no 
conclusion can be drawn regarding the effect 
of IVT on macular edema in BRVO. 
Many studies on IVT for BRVO have 
reported a rapid but temporary improvement 
in VA,10-18 which has often required additional 
injections to maintain improvement.11-15,18 In our 
study, we found a relatively swift response of 
Mean VA 
at baseline 
(logMAR)
VA change up to
month 4 (logMAR)†
P‑value
between 
groups
Mean CMT 
at baseline 
(µ)
CMT change up to
month 4 (µ)
P‑value
between 
groups Case Control Case Control
Non-ischemic 0.91 ± 0.38 -0.17 ± 0.15 0.25 ± 0.44 0.027 476 ± 136 -157 ± 177 127 ± 159 0.045
Ischemic 1.24 ± 0.47 -0.59 ± 0.77 -0.14 ± 0.51 0.224 597 ± 109 -229 ± 363 -177 ± 195 0.774
P-value within 
group
0.048 0.128 0.262 0.015 0.287 0.041
Table 4. Visual acuity and central macular thickness changes up to 4 months following intravitreal triamcinolone 
injection versus observation in acute branch retinal vein occlusion categorized by non-ischemic versus ischemic 
subtypes
† A decrease in logMAR notation reflects an increase in VA
VA, visual acuity; CMT, central macular thicknessIVT for Acute BRVO; Ramezani et al
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VA to IVT at one month. Although this effect 
decreased with time, it maintained a significant 
level up to month 3. The diminishing effect 
of treatment with IVT signifies the need for 
interventions with longer follow up. Compared 
to the control group, however, even this transient 
effect was not significant, which could be 
explained by the small sample size. 
We noticed a significant decrease of 
172 ± 202 microns in CMT at 4 months in IVT-
treated eyes in within-group analysis which 
is less than that reported in other studies. 
For instance, in a retrospective comparative 
study, mean CMT decreased from 518 ± 145 to 
292 ± 121 microns at three months (P = 0.001) 
following IVT.25 In another study, CMT was 
reported to decrease from 666 ± 291 microns 
at baseline to 351 ± 180 microns (P = 0.026) at 3 
months.4 Between-group differences were not 
significant regarding CMT reduction which 
could be due to the small number of cases in 
the current study. The anti-edema effect of 
IVT along with the improvement associated 
with the natural course of BRVO might have 
resulted in further reduction in CMT after 2 
months in our treatment group.
In the current trial, the amount of VA 
improvement and CMT reduction were more 
pronounced in eyes with ischemic BRVO. This 
may be explained by the lower VA and higher 
CMT at baseline in this subgroup, making a 
wider range of changes possible. Only in non-
ischemic eyes in our study, was a significant 
difference detected between the subgroups in 
terms of both VA and CMT changes, in favor 
of IVT. Such an improvement following IVT 
has also been shown in patients with non-
ischemic central retinal vein occlusion by Ip 
et al26. These investigators demonstrated a 
significant reduction in CMT following IVT in 
both non-ischemic and ischemic eyes; however, 
only non-ischemic patients showed statistically 
significant visual improvement. 
On the other hand, another clinical trial 
revealed a significant, although transient, 
benefit from IVT in terms of VA and CMT in 
both non-ischemic and ischemic central retinal 
vein occlusion.27 It should be noted that because 
of the small sample size in the mentioned 
study, any conclusion regarding non-ischemic 
vs. ischemic subtypes of the disease should be 
made with caution.
No catastrophic injection-related complica-
tion such as retinal detachment, infectious or 
sterile endophthalmitis, or vitreous hemorrhage 
developed in our cases. In the present study, 
ocular hypertension developed in six eyes 
which was controlled with medications in all 
cases. The rate of steroid-induced IOP rise was 
lower than other studies.14,27-30 
Regression of iris neovascularization after 
intravitreal injections of crystalline cortisone 
was reported by Jonas and associates.31 To 
our knowledge such a protective effect has 
not been proven in eyes with BRVO. In the 
current trial, neovascularization of the iris 
occurred in three eyes in the control group while 
neovascularization of the retina appeared in 
one eye of each study group. Due to the small 
number of cases with this complication, we 
could not reach any conclusion in this regard. 
To evaluate the preventive effect of IVT on 
iris neovascularization, a study with a larger 
number of cases is needed.
In the current study, sample size was 
calculated to allow detection of a 0.4 logMAR 
difference in VA change between the groups at 
four months. Based on the observed standard 
deviation in our study, the actual power of the 
study to detect such a difference was 60.2%. 
Accordingly, to be able to detect a difference as 
small as 0.24 logMAR, 63 and 84 cases in each 
group would have been required to achieve 
study power of 80% and 90%, respectively. 
However one should note that for such an 
intervention with its potential complications, 
a smaller intergroup difference may be of no 
clinical value. Nonetheless, small sample size 
and short follow up period may be considered 
as limitations of this study.
In summary, IVT injection was associated 
with slight and non-significant VA improvement 
one to three months after intervention as 
compared to the natural course of acute BRVO. 
Considering the temporary and non-significant 
effect of such therapy and its potential side 
effects, we recommend applying BVOS protocols 
for management of macular edema in eyes with IVT for Acute BRVO; Ramezani et al
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BRVO, i.e., defer treatment for three months 
and allow time for spontaneous resolution 
of macular edema. However, if a more rapid 
short-term recovery is desired, IVT can still be 
considered as an option. In this case, the need 
for repeat injections or other interventions, 
such as macular photocoagulation, should be 
kept in mind. 
Considering the promising effects of 
anti-vascular endothelial growth factor 
agents on retinal vein occlusions,32-37 further 
trials assessing the effects of these drugs are 
recommended.
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